• J L Severens, H M Oerlemans, A J Weegels, M A van 't Hof, R A Oostendorp, and R J Goris.
• Department of Medical Technology Assessment, University of Nijmegen, The Netherlands.
• Arch Phys Med Rehabil. 1999 Sep 1;80(9):1038-43.

ObjectiveTo study from a societal viewpoint the cost-effectiveness of adjuvant treatment for patients with reflex sympathetic dystrophy (RSD) of one upper extremity.DesignA two-center randomized clinical trial comparing pairwise physical therapy (PT), occupational therapy (OT), and control treatment (CT).PatientsOne hundred thirty-five patients with RSD for less than 1 year participated.InterventionsPT and OT were given according to protocols. For CT, services by social workers were offered.Main Outcome MeasuresThe Impairment-level Sum Score (ISS), the modified Greentest, and the Sickness Impact Profile (SIP) were used to determine effectiveness. Real medical costs, nonmedical costs, and productivity costs were distinguished and incremental cost-effectiveness ratios were calculated. Sensitivity analyses were performed on cost estimates.ResultsThe ISS, but not the Greentest and SIP, showed a significant difference between PT versus OT and CT. The mean adjuvant treatment costs were significantly higher for PT (Netherlands Guilders [NLG] 1,726) and OT (NLG 2,089) compared with CT (NLG 903). The mean total medical costs were not significantly different for the groups (PT, NLG 8,692; OT, NLG 13,023; and CT, NLG 7,888) (intention-to-treat analysis). The sensitivity analyses showed a moderate influence of the cost estimates.ConclusionsPT results in clinically relevant improvement in RSD. Costs associated with adjuvant treatment are moderate compared to other medical costs. The incremental cost-effectiveness ratios of PT versus OT and CT were moderate or even dominant, thus PT was both more effective and less costly than its comparators.

20 keywords...

hide…